Article
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Antiviral therapy - 1 Jan 2011
Hofmann Wolf Peter, Chung Tje Lin, Osbahr Carola, Susser Simone, Karey Ursel, Mihm Ulrike, Welsch Christoph, Lötsch Jörn, Sarrazin Christoph, Zeuzem Stefan, Herrmann Eva
Abstract excerpt
BACKGROUND: Ribavirin increases early and sustained virological response rates in patients chronically infected with HCV who receive pegylated interferon-α and novel HCV protease inhibitors. METHODS: To better characterize antiviral efficacies of these upcoming therapies, Huh7 cells harbouring a subgenomic HCV replicon system were cultivated with various doses and combinations of ribavirin, interferon-α, and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.